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Abstract
Introduction
•Inflammatory Bowel Disease (IBD) has been increasing in incidence over the 
past decade.  The effects of the disease on an individual and the potential life-
long cost of medical treatment are rationales to find and treat the cause of IBD. 
Researchers are evaluating altered gut flora as a cause of IBD.  Dysbiosis was 
identified as a feature of IBD and interventions directed at themicrobiome may 
be indicated in thetherapy of IBD (Kabeerdoss et al., 201).
Research Question
Literature Review
•Casen et al. (2015) termed the microbiota in a healthy patient “normobiosis”.  The purpose of 
this study was to obtain fecal samples and examine the relationship between dysbiosis and 
patients with IBD. Adult male and female patients ages 17-76 (n=330) were selected both with 
IBD and a control group of healthy individuals (n=165).  The fecal samples were probed 
targeting approximately 300 bacteria to identify dysbiosisusing the GA-map Dysbiosis Test 
(GA-test) to determine a Dysbiosis Index (DI). In this sample, a DI of >2 was associated with
dysbiosis.  In all samples collected from healthy individuals results were <2 with a mean of 1.72 
and in IBD both treatment naïve and in remission were >2 with a mean from 3.15-3.3. Results 
confirmed dysbiosis in 70-80% of IBS patients, IBD patients untreated, and IBD in remission 
vs 16% in healthy controls (Casen, et al., 2015).  Firmicutes, Proteobacteria, Actinobacteria
and Ruminociccus gnavus were predominant bacteria found associated with IBD.  
•Kaberdoss et al. (2013) studied the colonic mucosa of patients with IBD and healthy 
controls to determine alteration in microbial communities Biopsies of colonic mucosa was 
obtained in 32 patients with UC, 28 with CD, and 30 healthy controls during colonoscopy. 
Results produced a ratio of Firmicutes to Bacteroidetes was significantly decreased in patients 
with CD and UC compared to healthy controls indicating dysbiosis in IBD patients with 
P=0.0014 (Kabeerdoss, Jayakanthan, Pugazhendhi, & Ramakrishna, 2015).  Dysbiosis was 
identified as a feature of IBD and interventions directed at the microbiome may be indicated 
in the therapy of IBD (Kabeerdoss, Jayakanthan, Pugazhendhi, & Ramakrishna, 2015). 
•Olendski, B. et al. (2014) utilized an Anti-Inflammatory Diet (IBD-AID) to help treat 
symptoms of IBD. Dysbiosis is the theory behind this diet theorizing certain carbohydrates 
contribute to the proliferation of pathogenic bacteria (Olendzki, Silverstein, Cave, & 
Baldwin,2014). Eleven of 40 patients chose to remain on the diet and were reviewed by 
the Harvey Bradshaw Index (HBI) or the Modified Truelove and Witts Severity Index 
(MTLWSI) before and after the diet (Olendzki, Silverstein, Cave, & Baldwin, 2014). 
The MTLWSI mean was 7 (range 6-8) and the follow-up mean was 0.  The average decrease 
in the HBI was 9.5 and MTLWSI 7.   The sample group was fairly small and only 
approximately 25% were compliant for four weeks (Olendzki, Silverstein, Cave, & Baldwin, 
2014). 
Applicability to Clinical Practice
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Discussion
• Patients with IBD are in a state of gut dysbiosis (Ballal, Gallini, Segata, 
Huttenhower, & Garrett, 2011).   Evidence supports the theory that 
microbiota is altered in IBD patients (Kabeerdoss, Jayakanthan, 
Pugazhendhi, & Ramakrishna, 2015).  See Figure 1. Eventually, due to 
disruption of homeostasis in the gut flora, an inflammatory response occurs 
resulting in erosion of the mucosa of the gastrointestinal tract.   
Malabsorption of essential vitamins, minerals and nutrients is the result, 
leaving the body in a suboptimal state.
• Research has found genetic alterations of genes such as the NOD2 risking 
the development of IBD (Leone, Chang, & Devkota, 2013).  Atg16L1, 
IRGM, and IL-23R were other altered genes associated with patients with 
IBD (Ballal, Gallini, Segata, Huttenhower, & Garrett, 2011).  Testing for 
genetic components is not routinely performed in IBD but may have 
potential to prevent onset.  A study of using this testing as a predictor may 
be useful.   
• Study of fecal samples are proving helpful in identifying specific bacteria 
involvement and dysbiosis in IBD (Casen, et al., 2015).  Fecal and mucosal 
sampling to identify dysbiosis would prove beneficial and establish a 
foundation from which to treat the patient as an individual.  The causative 
imbalance of microbiota could potentially be replaced if properly 
identified.
• The theory that if diet is a causative component of IBD then diet should be 
a therapeutic treatment in IBD is of growing interest.   Restoring the gut 
microflora through proper nutrition may be a key component in the 
treatment and prevention of IBD (Olendzki, Silverstein, Cave, & Baldwin, 
2014).    Nutrition could be a successful adjunct in the treatment of IBD, 
decreasing the need for medication and preventing the need for surgical 
intervention in these patientsThe IBD-AID diet was 100% successful in 
decreasing the symptoms and dosage of medication of the IBD patients 
who complied with the diet but the study was small.   The need for a larger 
cohort study focusing on an individualized patient nutritional plan is 
needed as a result (Olendzki, Silverstein, Cave, & Baldwin, 2014). 
Inflammatory bowel disease (IBD) including Crohn’s Disease (CD) and 
Ulcerative Colitis (UC) has become a more common diagnosis.  The 
number of screenings for IBD has increased, drawing more attention to 
finding the cause.  Researchers are finding that a change in diet, increased 
stress levels, and overuse of antibiotics may contribute to IBD by changing 
the gut microbiota (Skrautvol et al., 2011; Bernstein, 2010). Prebiotics and 
probiotics, an individualized anti-inflammatory diet, and lifestyle 
modification to decrease stress are all currently undergoing evaluation to 
discover a possible role in the reversal of IBD insult to the normal flora of 
the gut.   This literature review examined IBD studies within the past eight 
years, including children and adults age 10-76, male and female who suffer 
from IBD and address gut microbiota.  Articles were reviewed from EBSCO 
and PubMed.  Cammorata et al. (2015) conducted research on fecal samples 
from patients with IBD (n=330) and healthy control (n=165) using a 
Dysbiosis Index (DI).  Dysbiosis was associated with a score of >2.  All 
healthy controls were <2 and IBD patients >2.  This was confirmed with an 
Illumina MiSeq test with P=<0.001.  Kabeerdoss, J. et al. (2013) researched 
biopsies from colonic mucosa of patients with IBD (n=60) compared with 
controls (n=30) undergoing screenings. A decreased ratio of Firmicutes to 
Bacteroidetes was identified in IBD patients with significance of P=0.0014 
proving an altered gut flora in IBD patients.  The population of patients 
examined with IBD who are able to restore their gut microbiota will likely 
decrease symptoms and decrease the need for long-term treatment with anti-
inflammatory medications.  Further research is needed to identify specific 
imbalances in microbiota with the application of results to create an 
individualized plan to restore gut flora as a key treatment to achieve and 
maintain remission in IBD patients.  
In patients with IBD will restoring gut microbiota 
eliminate or decrease the need for long-term 
treatment with medications?
Identifying patients at risk for development and exacerbation of IBD is an 
important role for primary care providers.  As genetic testing, fecal testing and 
microbiota testing becomes more widely used IBD could be prevented in the 
future.  Research has correlated nutrition’s impact on the gut microbiota but  
larger studies are needed.  Patients with IBD have an imbalance in their gut 
organisms that when balanced could create a state of normobiosis.   IBD-AID 
as a nutritional guide is an optimal approach to healing and reestablishig 
homeostasis of the gut microbiota (Olendzki, Silverstein, Cave, & Baldwin, 
2014). The success of the IBD-AID trial warrants a larger study group 
utilizing the IBD-AID diet vs the currently used anti-inflammatory drugs, 
steroids, biological drugs, and  surgery.  Similar results would support the 
benefit and the promote the use of the IBD-AID diet as a standard of care. 
Primary care providers and nutritionists can assist IBD patients, or those at 
risk of developing IBD due to genetic indicators, in staying adherent to an 
individualized nutrition plan that could decrease the need for the mainstay 
medications currently used to treat IBD.   Encouraging patient compliance and 
accountability for health is ongoing and imperative for success in the treatment 
of IBD.  Nutrition in the form of an anti-inflammatory diet has the potential to 
decrease the need for costly anti-inflammatory drugs, steroids, biological 
drugs and decrease their dangerous side effects but more research is needed to 
prove this.
The author extends gratitude to Dr. Vicky McCleary for serving as an advisor 
and mentor for this project.   
Statement of the Problem
•Patients diagnosed with ID are faced with the potential of life-long anti-
inflammatory drugs, steroiBds, biological drugs, and even surgery to decrease 
or control symptoms.  Documented side effects of these treatments are 
decreased immunity, renal failure, hepatotoxicity, exacerbations of the disease, 
myocarditis, blood dyscrasias, and anemia. The cost of the medication, side 
effects, hospitalizations and absenteeism from work add to the burden of 
patients with IBD.
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Figure 1.  Ratio of Firmicutes (C. coccoides plus C. leptum) to Bacteroidetes in the mucosal 
microbiota. The Figure shows the ratio in patients with CD and UC. CD-N and CD-Ab refer to 
Crohn’s disease normal and abnormal mucosa. UC-N and UC-Ab refer to ulcerative colitis normal 
and abnormal mucosa. Significant P values are shown above the bars in the Figure. None of the 
other differences was significant.  IBD biopsies showed a significantly lower ratio compared with 
controls. (Kabeerdoss, Jayakanthan, Pugazhendhi, & Ramakrishna, 2015)
